SCYNEXIS INC 8K

SCYNEXIS, Inc. used the 8‑K to furnish an investor deck detailing its acquisition and development plans for SCY‑770 in ADPKD and its strengthened financial position following a $40 million PIPE financing.

SCYNEXIS, Inc. furnished an investor presentation describing its strategic acquisition of global rights to SCY‑770, a Phase 2–ready, oral, direct AMPK activator for autosomal dominant polycystic kidney disease (ADPKD), including financial terms of the Poxel transaction ($8 million upfront, up to $8 million in development milestones tied to Phase 2 and Phase 3 initiation, and up to $180 million in commercial milestones with no royalties), its planned development path and timelines for Phase 2 and potential accelerated approval, the rare-disease market opportunity in ADPKD, and an updated financial outlook reflecting approximately $56 million of cash as of December 31, 2025, a recent $40 million PIPE financing extending cash runway into mid‑2029, and potential future milestone and royalty income from the BREXAFEMME license with GSK.

Filing Facts

CIK

1178253

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-134476

Alert Tier

7